These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 12482641)

  • 1. The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients.
    Tankova T; Koev D; Dakovska L; Kirilov G
    Diabetes Res Clin Pract; 2003 Jan; 59(1):43-9. PubMed ID: 12482641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
    Ma J; Liu LY; Wu PH; Liao Y; Tao T; Liu W
    J Diabetes Res; 2014; 2014():294017. PubMed ID: 24772445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of repaglinide added to sitagliptin in Japanese patients with type 2 diabetes: A randomized 24-week open-label clinical trial.
    Nishimura A; Usui S; Kumashiro N; Uchino H; Yamato A; Yasuda D; Nagasawa K; Okubo M; Mori Y; Hirose T
    Endocr J; 2016 Dec; 63(12):1087-1098. PubMed ID: 27647480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
    Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
    Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
    Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
    Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
    Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial.
    Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM
    Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
    Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
    Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
    Li J; Tian H; Li Q; Wang N; Wu T; Liu Y; Ni Z; Yu H; Liang J; Luo R; Li Y; Huang L
    Diabetes Obes Metab; 2007 Jul; 9(4):558-65. PubMed ID: 17587398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
    Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
    Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
    Wolffenbuttel BH; Landgraf R
    Diabetes Care; 1999 Mar; 22(3):463-7. PubMed ID: 10097930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
    Van Gaal LF; Van Acker KL; De Leeuw IH
    Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
    Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
    Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
    Rosenstock J; Hassman DR; Madder RD; Brazinsky SA; Farrell J; Khutoryansky N; Hale PM;
    Diabetes Care; 2004 Jun; 27(6):1265-70. PubMed ID: 15161773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea.
    Omori K; Nomoto H; Nakamura A; Takase T; Cho KY; Ono K; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2019 Mar; 10(2):367-374. PubMed ID: 29963781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repaglinide in combination therapy with metformin in Type 2 diabetes.
    Moses R
    Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S136-9. PubMed ID: 10522839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
    Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
    Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.